Dyne Therapeutics (DYN) Competitors

Grifols (NASDAQ:GRFS) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability.

Does the MarketBeat Community favor GRFS or DYN?

Grifols received 304 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 78.69% of users gave Dyne Therapeutics an outperform vote while only 56.23% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Grifols	Outperform Votes 352 56.23%	Underperform Votes 274 43.77%
Dyne Therapeutics	Outperform Votes 48 78.69%	Underperform Votes 13 21.31%

Do insiders and institutionals hold more shares of GRFS or DYN?

96.7% of Dyne Therapeutics shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is GRFS or DYN more profitable?

Grifols' return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	N/A	N/A	N/A
Dyne Therapeutics	N/A	-57.46%	-51.62%

Which has more volatility & risk, GRFS or DYN?

Grifols has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Does the media refer more to GRFS or DYN?

In the previous week, Dyne Therapeutics had 1 more articles in the media than Grifols. MarketBeat recorded 5 mentions for Dyne Therapeutics and 4 mentions for Grifols. Grifols' average media sentiment score of 1.04 beat Dyne Therapeutics' score of 0.76 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, GRFS or DYN?

Grifols has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$7.21B	0.86	$64.20M	$1.17	7.71
Dyne Therapeutics	N/A	N/A	-$235.94M	-$3.59	-4.12

Do analysts rate GRFS or DYN?

Dyne Therapeutics has a consensus target price of $45.54, suggesting a potential upside of 208.11%. Given Dyne Therapeutics' higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Dyne Therapeutics	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.07

Summary

Grifols beats Dyne Therapeutics on 9 of the 17 factors compared between the two stocks.